1. Home
  2. HAFC vs TBPH Comparison

HAFC vs TBPH Comparison

Compare HAFC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

HOLD

Current Price

$30.09

Market Cap

898.1M

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.05

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAFC
TBPH
Founded
1982
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
898.1M
824.9M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
HAFC
TBPH
Price
$30.09
$16.05
Analyst Decision
Hold
Buy
Analyst Count
3
6
Target Price
$32.17
$18.40
AVG Volume (30 Days)
195.3K
289.3K
Earning Date
04-21-2026
05-04-2026
Dividend Yield
3.75%
N/A
EPS Growth
22.44
279.13
EPS
0.75
N/A
Revenue
$270,165,000.00
$15,386,000.00
Revenue This Year
$18.65
$8.46
Revenue Next Year
$7.28
N/A
P/E Ratio
$40.10
N/A
Revenue Growth
15.28
N/A
52 Week Low
$22.00
$9.98
52 Week High
$31.33
$21.03

Technical Indicators

Market Signals
Indicator
HAFC
TBPH
Relative Strength Index (RSI) 55.43 40.51
Support Level $29.00 $13.41
Resistance Level $30.47 $17.21
Average True Range (ATR) 0.56 0.34
MACD -0.04 -0.06
Stochastic Oscillator 60.56 4.84

Price Performance

Historical Comparison
HAFC
TBPH

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: